Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
Clinical trial NCT07718737 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07718737
- Sponsor
- Multitude Therapeutics Inc.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-28
- Primary completion
- 2028-03-30
- Enrollment
- 512
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.